Jump to content

Drilldown: Medicines

Pharmacopedia
BrowseCategoriesLog in
Pharmacopedia is being built in public. Pages may be incomplete.About this site

Choose a table:


Medicines > classes : Classic Psychedelic or Dissociative or [[:Category:Biologics|Biologic]]

Use the filters below to narrow your results.

generic:
brand:
None (86) · Delysid (historical, Sandoz, withdrawn 1965) (1) · DXM (1) · DXO (1) · Humira; biosimilars Amjevita, Cyltezo, Hadlima, Hulio, Hyrimoz, Idacio, Yusimry, Abrilada (1) · Repatha (1) · Spravato (1)
classes: (Click arrow to add another value)
mechanism:
5-HT2A agonist (26) · Potent 5-HT2A agonist (5) · LSD analogue; 5-HT2A agonist (4) · Prodrug of LSD; 5-HT2A agonist (4) · NMDA antagonist (3) · None (2) · Contains LSA (2) · Contains mescaline (2) · NMDA antagonist; sigma receptor agonist (2)
uses:
None (90) · Treatment-resistant depression (TRD) in adults, as adjunct to oral antidepressant (FDA-approved March 2019). Depressive symptoms in adults with MDD with acute suicidal ideation or behavior (FDA-approved Aug 2020). (1) · '"`UNIQ--vote-0000147C-QINU`"', '"`UNIQ--vote-0000147D-QINU`"', '"`UNIQ--vote-0000147E-QINU`"' (1)
starting dose:
None (89) · 140 mg SC every 2 weeks OR 420 mg SC monthly (3 consecutive injections 5 minutes apart due to volume) (1) · 40 mg SC every other week (most adult indications); IBD induction 160 mg week 0, 80 mg week 2, then 40 mg every other week (1) · Induction (TRD): 56 mg intranasal twice weekly × 4 weeks. Maintenance: 56-84 mg once weekly × 4 weeks, then 56-84 mg every 1-2 weeks. For acute suicidality: 84 mg twice weekly × 4 weeks. Administered under medical supervision in REMS-certified site. (1)
preparations:
None (89) · 140 mg/mL single-use prefilled syringe and SureClick autoinjector; Pushtronex 420 mg/3.5 mL on-body infusor (1) · 28 mg/device (each dose uses 2 devices) (1) · 40 mg/0.4 mL or 40 mg/0.8 mL prefilled syringe and autoinjector pen; 10, 20, 80 mg pediatric/induction strengths (1)
fda max:
None (89) · 40 mg every week (selected indications); otherwise 40 mg every other week (1) · 420 mg/month (1) · 84 mg per session (1)
routes:
None (88) · Intranasal (under direct medical supervision) (1) · Oral (1) · Subcutaneous (2)
onset:
None (88) · 30–60 minutes (1) · LDL reduction ~50-60% from baseline at 1-2 weeks (1) · Symptomatic effect within weeks; full response by 12-24 weeks (1) · Within hours of first administration (1)
duration:
None (88) · 2 weeks per dose (1) · 2-4 weeks per dose (1) · 8–12 hours (1) · Acute effect ~24 hours; cumulative effect builds with repeated dosing (1)
halflife:
None (88) · 3–5 hours (1) · ~11-17 days'"`UNIQ--ref-0000147F-QINU`"' (1) · ~14 days'"`UNIQ--ref-00001103-QINU`"' (1) · ~7-12 hours (1)
bioavailability:
None (88) · 70–90% (oral) (1) · ~48% intranasal (1) · ~64% from SC depot'"`UNIQ--ref-00001104-QINU`"' (1) · ~72% from SC depot'"`UNIQ--ref-00001480-QINU`"' (1)
pregnancy:
None (89) · Avoid; may cause fetal harm (1) · Limited data.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1) · Not established (1)
legal:
None (89) · Rx, Schedule III (US). REMS program required. (1) · Schedule I (United States) (1) · [[USLegal:Prescription only|Rx-only]] in US (1)

Showing below up to 92 results in range #1 to #92.

View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)


View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"